Cannabis Bioavailability by Consumption Method: How Much THC Actually Reaches Your Bloodstream

When you consume 10 milligrams of THC, your body does not absorb all 10 milligrams. Depending on how you consume it, you may absorb as little as 4 percent or as much as 56 percent of the active compound. The rest is destroyed by heat, filtered by your liver, trapped in fat tissue, or simply never crosses the membranes needed to reach systemic circulation. This gap between what you consume and what your body actually uses is called bioavailability, and it is the single most important pharmacokinetic concept for any cannabis consumer to understand.

Bioavailability explains why a 10-milligram edible feels different from a 10-milligram dab. It explains why sublingual tinctures hit faster than brownies. It explains why topical creams can reduce localized pain without producing any psychoactive effect. And it explains why two people consuming the same product can have wildly different experiences.

This article breaks down the bioavailability of every major cannabis consumption method, using data from published clinical pharmacokinetic studies. We will cover how much THC reaches your bloodstream, how fast it gets there, how long it stays, and what factors influence absorption for each route of administration.

Inhalation: Smoking

Smoking remains the most common method of cannabis consumption worldwide, and it offers one of the highest bioavailability rates of any route. Clinical studies consistently show that smoking delivers between 20 and 56 percent of the available THC to the bloodstream, with experienced consumers trending toward the higher end of that range.

The mechanism is straightforward. When cannabis combusts, THC vaporizes and is carried into the lungs on smoke particles. The alveolar surface of human lungs offers roughly 70 square meters of thin, highly vascularized membrane. THC crosses this membrane in seconds, enters pulmonary blood flow, and reaches the brain within two to three minutes.

Peak plasma concentrations occur between three and ten minutes after the first inhalation. A single joint containing approximately 20 milligrams of THC typically produces peak blood levels between 100 and 200 nanograms per milliliter in occasional users. The psychoactive effects plateau within 15 to 30 minutes and begin to decline after about two hours, with residual effects fading over four to six hours.

The wide bioavailability range — 20 to 56 percent — is largely a function of inhalation technique. Deeper inhalation, longer breath-holding, and more efficient burning all increase absorption. Combustion itself destroys approximately 30 percent of the THC before it can be inhaled, which is the primary limitation of this method.

For a deeper look at specific smoking devices, our guide to portable dab rigs covers concentrated formats that modify these dynamics significantly.

Inhalation: Vaporization

Vaporization heats cannabis below the point of combustion, typically between 180 and 210 degrees Celsius. This avoids the thermal destruction of cannabinoids that occurs during smoking and eliminates most of the harmful byproducts of combustion. The result is a cleaner delivery mechanism with a comparable — and in some cases superior — bioavailability profile.

Studies place vaporization bioavailability between 30 and 60 percent, a modest improvement over smoking. The higher floor reflects the reduced loss to combustion. Peak plasma levels are reached within three to five minutes, similar to smoking, and the overall duration and intensity curve closely mirrors inhalation via combustion.

One notable difference is efficiency per milligram. Volcano-style vaporizers in clinical settings have demonstrated the ability to extract up to 80 percent of the available THC from plant material, compared to roughly 50 percent extraction during combustion. This means less raw material is needed to achieve equivalent blood levels.

For consumers weighing the practical tradeoffs between vaping devices, our vape pen comparison covers the current hardware landscape.

Temperature matters. Below 170 degrees Celsius, extraction is incomplete and bioavailability drops. Above 230 degrees, partial combustion begins and the advantages over smoking diminish. The sweet spot for most cannabinoids is 185 to 210 degrees Celsius.

Oral: Edibles

Edibles are the most popular non-inhalation method, and they have the most misunderstood bioavailability of any consumption route. When you swallow a THC-containing edible, the compound must survive stomach acid, be absorbed through the intestinal wall, and then pass through the liver before entering general circulation. This process — called first-pass metabolism — converts a significant portion of delta-9-THC into 11-hydroxy-THC, a metabolite that crosses the blood-brain barrier more readily and produces a more intense, longer-lasting psychoactive effect.

Oral bioavailability of delta-9-THC ranges from 4 to 20 percent, with most studies centering around 6 to 10 percent. This is dramatically lower than inhalation. However, the story is more complex than the numbers suggest, because the 11-hydroxy-THC metabolite produced during first-pass metabolism is itself psychoactive — some researchers argue it is two to four times more potent at the CB1 receptor than the parent compound.

Onset is slow. Peak plasma concentrations of delta-9-THC typically occur 60 to 120 minutes after ingestion, though individual variation is enormous. Gastric emptying rate, body fat percentage, recent food consumption, and individual liver enzyme expression all influence absorption timing. Some consumers do not reach peak effects for three hours or more. The total duration of psychoactive effects ranges from four to eight hours, with some consumers reporting residual effects lasting 12 hours after a high dose.

This slow, unpredictable onset is why dosing mistakes with edibles are so common. Our beginner’s edible guide covers practical strategies for managing the experience, while the science of munchies and appetite explores how oral THC interacts with digestive signaling.

Oral: Nano-Emulsion and Fast-Acting Edibles

A newer category of oral products uses nano-emulsion technology to improve both the speed and consistency of THC absorption. These formulations break THC oil into particles between 20 and 100 nanometers in diameter, dramatically increasing the surface area available for absorption and allowing partial uptake through the oral and gastric mucosa before the compound reaches the liver.

Clinical data on nano-emulsified THC products is still emerging, but manufacturer-sponsored studies and independent pharmacokinetic analyses suggest bioavailability between 15 and 35 percent — a significant improvement over traditional edibles. Onset times drop to 10 to 20 minutes, much closer to the inhalation curve.

The trade-off is duration. Because nano-emulsified THC bypasses much of the first-pass metabolism that generates 11-hydroxy-THC, the subjective effect often peaks faster and fades sooner — more like three to four hours than six to eight. For a full breakdown of this technology, see our nano-emulsion fast-acting cannabis guide.

Sublingual: Tinctures and Strips

Sublingual administration — holding a tincture, oil, or dissolvable strip under the tongue — exploits the thin, highly vascularized mucous membrane beneath the tongue. THC and other cannabinoids absorb directly into the sublingual vein, which drains into the internal jugular vein, bypassing the portal circulation and avoiding first-pass liver metabolism entirely.

Bioavailability via the sublingual route is estimated between 12 and 35 percent, depending on formulation and hold time. The critical variable is patience. Most of the absorption occurs in the first two to four minutes of mucosal contact. Swallowing too quickly converts the delivery to an oral route with standard first-pass dynamics.

Onset occurs in 15 to 45 minutes, faster than traditional edibles but slower than inhalation. Peak effects arrive between 30 and 90 minutes. Duration is moderate, typically three to five hours.

Alcohol-based tinctures generally outperform oil-based tinctures in sublingual absorption because ethanol acts as a penetration enhancer across mucosal tissue. MCT oil tinctures, while gentler on the mouth, absorb more slowly and more of the dose tends to be swallowed and processed orally.

Topical: Creams, Balms, and Patches

Topical cannabis products applied to the skin face the stratum corneum — the outermost layer of dead skin cells that serves as the body’s primary barrier against environmental compounds. THC is a lipophilic molecule with a molecular weight around 314 daltons, which places it right at the edge of what can permeate skin effectively.

Standard topical creams and balms deliver THC to local tissue — muscles, joints, peripheral nerves — but essentially zero THC reaches systemic circulation. Bioavailability in the traditional sense is effectively 0 percent. There is no psychoactive effect. The therapeutic mechanism is entirely local, mediated by CB1 and CB2 receptors in the skin, subcutaneous fat, and underlying muscle tissue.

Transdermal patches are a different category. These use permeation enhancers and occlusive adhesive systems to push cannabinoids through the stratum corneum into the capillary bed of the dermis. Transdermal bioavailability varies widely by formulation, with published estimates ranging from 10 to 45 percent depending on the enhancer technology used. Onset is slow — one to two hours — but duration can extend 8 to 12 hours with a flat, sustained-release profile.

Rectal: Suppositories

Rectal administration is the least discussed but pharmacologically one of the most interesting routes. The lower rectum is drained by the inferior rectal veins, which feed into the internal iliac veins and bypass the portal circulation entirely. This means that properly formulated rectal suppositories can avoid first-pass metabolism in a manner similar to sublingual delivery.

Published bioavailability data for rectal THC is limited, but available studies suggest systemic absorption between 13 and 50 percent, with onset in 10 to 30 minutes. The rectal mucosa is less permeable than the alveolar membrane but significantly more permeable than the skin or the sublingual membrane for lipophilic compounds.

The clinical relevance is primarily for patients who cannot take oral medications — those with nausea, vomiting, gastrointestinal surgery, or swallowing difficulties. The psychoactive profile is similar to sublingual administration, with moderate intensity and duration.

Variables That Change Everything

Bioavailability is not a fixed number for any route. Several individual factors create the wide ranges seen in clinical data.

Body composition matters significantly for oral and sublingual routes. THC is extremely lipophilic, and individuals with higher body fat percentages sequester more THC in adipose tissue before it reaches the brain. This can delay onset and reduce peak intensity while extending duration.

Tolerance and receptor density do not change bioavailability per se — the same amount of THC reaches the blood — but they dramatically change the subjective response to a given blood level. Experienced consumers may need blood levels three to five times higher than naive users to achieve equivalent psychoactive effects.

Food and metabolism alter oral bioavailability substantially. A high-fat meal consumed 30 minutes before an edible can increase THC absorption by two to five times. Cytochrome P450 enzyme variants — particularly CYP2C9 and CYP3A4 polymorphisms — create significant interpersonal differences in first-pass metabolism rates. Our piece on blood type and edible metabolism research examines some of these genetic factors.

Formulation is the variable most under manufacturer control. Lipid-based carriers, surfactants, cyclodextrins, and nano-emulsification all modify absorption rates within a given route. The same 10 milligrams of THC in different vehicles can produce meaningfully different pharmacokinetic curves.

Practical Takeaways

For consumers choosing between methods, the bioavailability data points toward a few clear principles. Inhalation remains the most efficient delivery method, offering the fastest onset and the most control over dosing in real time. Edibles deliver less THC per milligram but produce longer, more intense effects due to 11-hydroxy-THC conversion. Sublingual products occupy a useful middle ground. Topicals are ideal for localized relief without systemic effects. And nano-emulsion technology is rapidly closing the gap between oral and inhaled delivery.

Understanding these differences does not just help you choose a product. It helps you understand why the same nominal dose — 10 milligrams on the label — can produce experiences ranging from barely perceptible to overwhelming, depending entirely on how that dose enters your body.